Summary:
In this issue of Blood Cancer Discovery, Kotini and colleagues present a strategy for large-scale reprogramming of primary human acute myeloid leukemias (AML) to induced pluripotent stem cell (iPSC). They show that the hematopoietic differentiation of AML iPSCs gives rise to transplantable leukemias with remarkable molecular similarity to the original patients’ AML, providing new models and insights into the disease.
This content is only available via PDF.
©2023 American Association for Cancer Research
2023
American Association for Cancer Research
You do not currently have access to this content.